Management & Regulatory

How Will Oruka Therapeutics Transform Chronic Skin Disease Treatment?
Management & Regulatory How Will Oruka Therapeutics Transform Chronic Skin Disease Treatment?

Chronic skin diseases like plaque psoriasis have long posed significant challenges for patients and medical professionals alike, with existing treatments often falling short in efficacy and patient compliance. However, the emergence of Oruka Therapeutics, Inc. is positioned to revolutionize the

Insider Buying Signals Confidence as Analysts Downgrade Theravance
Management & Regulatory Insider Buying Signals Confidence as Analysts Downgrade Theravance

Theravance Biopharma Inc. (NASDAQ: TBPH) has recently garnered significant attention due to a series of notable insider transactions, varied analyst ratings, and fluctuating stock performance. These events offer deep insights into the current state and future trajectory of the company, presenting a

How Will AstraZeneca’s $135M Sweden Plant Expansion Impact Biologics?
Management & Regulatory How Will AstraZeneca’s $135M Sweden Plant Expansion Impact Biologics?

AstraZeneca has set the wheels in motion to significantly expand its biomanufacturing capacities with a $135 million investment in the Sweden Biomanufacturing Center in Södertälje. This venture marks the company's largest single investment in the facility since its inception in 2021, i

Bora Pharmaceuticals Expands with Tanvex Stake and Key Acquisitions
Management & Regulatory Bora Pharmaceuticals Expands with Tanvex Stake and Key Acquisitions

Bora Pharmaceuticals' recent strategic maneuvers have significantly bolstered its presence in the Contract Development and Manufacturing Organization (CDMO) sector, showcasing its intent to become a top contender in the biomanufacturing industry. In a notable move, Bora has acquired a 30.5%

What Are Theravance Biopharma’s Prospects Amidst Mixed Signals?
Management & Regulatory What Are Theravance Biopharma’s Prospects Amidst Mixed Signals?

Theravance Biopharma Inc (NASDAQ: TBPH) has been navigating a complex landscape filled with mixed signals, affecting its market performance and generating varied sentiment among analysts and investors alike. This article delves into recent developments surrounding the company, including key

Enzo Biochem Settles for $4.5M Over 2023 Data Breach, Tightens Security
Management & Regulatory Enzo Biochem Settles for $4.5M Over 2023 Data Breach, Tightens Security

In a significant move reflecting the growing regulatory pressure on data security practices, Enzo Biochem has reached a settlement with the Attorneys General of Connecticut, New York, and New Jersey over allegations of inadequate security measures leading to a data breach earlier this year. The

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later